First-line treatment for stage III NSCLC is chemoradiation; surgery, possibly quite extensive and involving induction therapy with chemotherapy or chemoradiotherapy, may be an option for stage IIIa tumors, whereas additional therapies for stages IIIb and c are combinations of chemotherapy and/or therapies targeting tumor mutations (e.g., epidermal growth factor receptor inhibitors, anaplastic lymphoma kinase (ALK) therapy) or immunotherapies. Here, ALK is linked to neoplasm.